On a similar note, cancers with the deficient HR genes RAD51C, RAD51D and PALB2 being treated with PARP inhibitors subjected to secondary mutations allowed for the induction of proper, or semi-proper, protein functioning, leading to a restoration of sufficient HR and PARPi resistance [130,131,132]. This evidence concerns the gene PARP1 and cancer.